Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Stock Information for Adamis Pharmaceuticals Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
Adamis Pharmaceuticals Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.